KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Assets (2016 - 2025)

Teva Pharmaceutical Industries' Assets history spans 17 years, with the latest figure at $40.7 billion for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 3.62% year-over-year to $40.7 billion, compared with a TTM value of $40.7 billion through Dec 2025, up 3.62%, and an annual FY2025 reading of $40.7 billion, up 3.62% over the prior year.
  • Assets for Q4 2025 was $40.7 billion at Teva Pharmaceutical Industries, up from $39.9 billion in the prior quarter.
  • The five-year high for Assets was $49.2 billion in Q2 2021, with the low at $38.4 billion in Q1 2025.
  • Average Assets over 5 years is $43.6 billion, with a median of $43.3 billion recorded in 2023.
  • Year-over-year, Assets fell 11.43% in 2021 and then increased 3.62% in 2025.
  • Tracing TEVA's Assets over 5 years: stood at $47.7 billion in 2021, then dropped by 7.67% to $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then decreased by 9.55% to $39.3 billion in 2024, then grew by 3.62% to $40.7 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Assets are $40.7 billion (Q4 2025), $39.9 billion (Q3 2025), and $40.1 billion (Q2 2025).